Vortex Vein Decompression for Nanophthalmic Uveal Effusion

Brockhurst, Robert J.

doi:10.1001/archopht.1980.01020040839008

Cited by 148 publications

(87 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Still, it is of interest that several distinctive features of this defined subset of patients are typical of this genetically heterogeneous disorder (7,8,9). This unity of phenotype suggests that nanophthalmos mutations may affect several different components of a single ocular growth mechanism.…”

Section: Discussionsupporting

confidence: 40%

See 1 more Smart Citation

Developmental Basis of Nanophthalmos:MFRPIs Required for both Prenatal Ocular Growth and Postnatal Emmetropization

Sundin

Dharmaraj

Bhutto

et al. 2008

Ophthalmic Genetics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 40%

“…Although this disorder has a number of synonyms, including posterior microphthalmia, most patients share a set of distinctive features. They have an axial length of 21 mm or less, a high corneal curvature, with surrounding choroidal and scleral layers that are much thicker than normal (6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 48%

Developmental Basis of Nanophthalmos:MFRPIs Required for both Prenatal Ocular Growth and Postnatal Emmetropization

Sundin

Dharmaraj

Bhutto

et al. 2008

Ophthalmic Genetics

View full text Add to dashboard Cite

show abstract

“…Several authors have reported a high incidence of postoperative complications in nanophthalmic eyes, with severe uveal effusion and total retinal detachment a few days after surgery (Brockhurst 1975;Singh et al 1982;Jin & Anderson 1990). The sudden drop in IOP to zero, that occurs during a peripheral iridectomy, results in a relative increase in the choroidal venous pressure and an aggravation of the uveal effusion (Brockhurst 1980). Consequently, non-invasive therapy, like laser iridotomy or gonioplasty, is considered to be the treatment of choice in nanophthalmic angle closure (Singh et al 1982).…”

Section: Discussioncontrasting

confidence: 38%

“…The underlying cause may be the thickened sclera leading to an obstruction of the vortex veins and a reduced transscleral drainage of proteinrich fluid from the suprachoroidal space (Brockhurst 1980;Gass 1983). The uveal effusion can occur spontaneously or as a complication to glucoma surgery, leading to both choroidal and retinal detachment (Brockhurst 1980;Ryan et al 1982).…”

mentioning

confidence: 42%

Exudative retinal detachment in nanophthalmos

Krohn

Seland

1998

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To report the treatment of exudative retinal detachment in a patient with nanophthalmos. Methods: A 46-year-old man with bilateral nanophthalmos suffered from acute angle-closure glaucoma in his left eye. The first day after a peripheral iridectomy an exudative retinal detachment was obseved. Two months later a partial thickness sclerectomy with a central sclerostomy, covered by a thin film of absorbable gelatine, was performed in each quadrant of the left eye. Results: The retinal detachment gradually resolved and after eight months the retina was completely reattached. Vision, which had been limited to hand movements, improved to 6/18 with correction. Conclusion: Scleral resections are effective in the treatment of nanophthalmic retinal detachment. The use of absorbable gelatine film to cover the sclerectomized area may prevent regeneration of scleral tissue and recurrence of the exudative retinal detachment.

show abstract

“…Thickening of the sclera has been implicated in the pathogenesis of uveal effusion and serous retinal detachment in patients with nanophthalmos. [11][12][13][14] Brockhurst 15 introduced vortex vein decompression with lamellar scleral resection, which reduced high venous pressure in choriocapillaris, thereby reducing the leakage of fluid and proteins. However, the surgery was difficult to perform because considerable bleeding occurred during removal of the sclera around the vortex vein.…”

Section: Discussionmentioning

confidence: 99%

Management of glaucoma in patients with nanophthalmos

Yalvaç

Şatana

Özkan

et al. 2007

Eye

View full text Add to dashboard Cite

Aims In this retrospective study, we aimed to evaluate the results of glaucoma surgery in patients with nanophthalmos. Methods Twenty-eight bilateral nanophthalmic patients, of whom 20 patients underwent trabeculectomy þ Mitomycin-C (MMC) þ inferior sclerotomy between 1996 and 2004, were included in this study. Records of patients with nanophthalmos were reviewed. Intraocular pressure (IOP), glaucoma medications, surgical success, visual acuity and complications were analyzed. Results The mean IOP was 34.675.3 mm Hg preoperatively. At the final follow-up visit, the mean IOP dropped to 21.4177.34 mm Hg (Po0.05). The cumulative probability of success was 85% at 1 year, 78.5% at 2 years, 76.9% at 3 years, 70.6% at 4 years and 47% at 5 years after surgery. Visual acuity decreased in 13 (65%) patients but no eye lost vision. Sequels of choroidal detachment (five patients 25%) and retinal folds (four patients 20%) were the most frequent reason for visual decrease. Uveal effusion (10 patients 50%) and cataract formation (seven patients 35%) were major late postoperative complications. Conclusions Results indicate that trabeculectomy þ MMC þ inferior sclerotomy procedure was effective and safe for glaucoma control in patients with nanophthalmos, but uveal effusion is a major problem and cataract surgery is expected in the long run.

show abstract

Vortex Vein Decompression for Nanophthalmic Uveal Effusion

Cited by 148 publications

References 6 publications

Developmental Basis of Nanophthalmos:MFRPIs Required for both Prenatal Ocular Growth and Postnatal Emmetropization

Developmental Basis of Nanophthalmos:MFRPIs Required for both Prenatal Ocular Growth and Postnatal Emmetropization

Exudative retinal detachment in nanophthalmos

Management of glaucoma in patients with nanophthalmos

Contact Info

Product

Resources

About